Does UnitedHealthcare Cover Prolia?
The verdict
Covered on most plans
UnitedHealthcare covers denosumab, but per UHCprovider.com, effective September 1, 2025, the interchangeable biosimilars Jubbonti (denosumab-bddz) and Wyost now replace Prolia and Xgeva, respectively, on UHC Medicare Advantage plans, Medicare Prescription Drug Plans, and most employer-group Medicare Advantage plans. Existing Prolia authorizations transitioned automatically. Denosumab is administered in the clinician's office every 6 months and billed under the medical benefit (HCPCS J0897) for most UHC members — not dispensed as a Part D pharmacy drug. The $2,100 Part D out-of-pocket cap does not apply to the Part B medical pathway.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with UnitedHealthcare using your member ID.
Key facts
Effective September 1, 2025, UHC officially transitioned all Medicare Advantage and most employer-group MA plans from branded Prolia to the interchangeable biosimilar Jubbonti (denosumab-bddz); existing authorizations carried over automatically.
UHCprovider.com — Jubbonti and Wyost biosimilar transition announcement, 2025
Jubbonti is the Prolia biosimilar (60 mg, osteoporosis); Wyost is the Xgeva biosimilar (120 mg, oncology). They are different products — confirm which applies to your indication before the transition.
Amgen Jubbonti and Wyost prescribing information; UHCprovider.com
Prolia and Jubbonti are Part B medical-benefit drugs for most UHC Medicare members — not Part D pharmacy drugs. The $2,100 Part D out-of-pocket cap does not apply to the Part B pathway.
CMS Local Coverage Determination L33394; Medicare.gov
Medicare vs. commercial coverage
Whether UnitedHealthcare covers Prolia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Advantage and Medicare Prescription Drug Plans (Part B medical benefit — operative pathway): per UHCprovider.com, 'Effective Sept. 1, 2025, Jubbonti and Wyost now replace Prolia and Xgeva, respectively, as interchangeable biosimilar products for UnitedHealthcare Medicare Advantage plans, Medicare Prescription Drug Plan and most employer group Medicare Advantage plans.' Denosumab is administered in-office as a subcutaneous injection every 6 months and billed under HCPCS J0897 incident to a physician service per LCD L33394. Prior authorization via UHC/OptumRx medical policy is required (osteoporosis with high fracture risk documentation). Existing Prolia authorizations transitioned to Jubbonti automatically. On the medical-benefit pathway, the member pays the plan's Part B drug copay or 20% coinsurance after the Part B deductible on Original Medicare — observed MA copays range $0–$500 per injection. The $2,100 Part D out-of-pocket cap does NOT apply to Part B drugs. Wyost (denosumab-bddz, 120 mg) replaces Xgeva for oncology/bone-metastasis indications and is a separate product — this page covers Prolia (osteoporosis, 60 mg) and its biosimilar Jubbonti.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: covered under the medical benefit with PA via UHC/OptumRx medical policy; documentation of osteoporosis with high fracture risk (T-score at or below -2.5, prior fragility fracture, or high FRAX score) required. Employer-group Medicare Advantage plans moved to Jubbonti effective September 1, 2025 in line with the broader UHC interchangeable-biosimilar transition. Non-Medicare commercial employer plans: PA required; biosimilar preference likely to follow. ACA/Individual: covered with PA where offered. Medicaid: UHC Community Plan Medicaid covers denosumab for approved osteoporosis indications per state PDL at nominal cost-share with PA. Not covered outside FDA-approved indications.
The 3 boxes you must tick to get approved
Commercial plans that will consider Prolia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Prolia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,786–$2,507 per 60 mg denosumab dose without insurance (estimates: Medicare.org ~$1,786 for Prolia; Jubbonti expected to list lower. GoodRx ~$2,507 for Prolia). Cash prices are estimates and vary by site of care.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Advantage (UHC): observed copays on Medicare plans range $0–$500 per injection depending on plan design — verify on your specific UHC MA plan benefit documents. Original Medicare with a Medigap supplement: 20% Part B coinsurance after the Part B deductible; Medigap typically covers the 20%, reducing out-of-pocket to $0. Commercial/Employer: medical-benefit coinsurance per UHC plan design. Medicaid: nominal cost-share per state PDL.
Typical monthly copay once prior authorization is approved.
Bridge program
Amgen offers copay support for Prolia for commercially insured patients. This program is NOT available to Medicare or Medicaid beneficiaries under federal anti-kickback rules. Most UHC members are on Medicare or employer plans, not commercial.
Reduced copay through the assistance program, where eligible.
All figures are estimates. The Part D $2,100 out-of-pocket cap does NOT apply to the Part B medical pathway — Jubbonti/Prolia is a Part B drug for most UHC members on Medicare. Verify your specific cost-share at myuhc.com or by calling UHC member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm the Jubbonti transition status for your specific UHC plan
Log in to myuhc.com and check your plan's drug and medical benefit documents for denosumab. Effective September 1, 2025, all UHC Medicare Advantage and most employer-group MA plans moved to Jubbonti as the covered product. If your prescriber wrote for Prolia, your pharmacy or clinic may have received notice that Jubbonti will be dispensed instead. Confirm the transition was applied to your authorization with your prescriber or UHC member services.
- 2
Understand the difference between Jubbonti and Wyost — and which applies to you
Jubbonti (denosumab-bddz, 60 mg) is the interchangeable biosimilar for Prolia, indicated for osteoporosis. Wyost (denosumab-bddz, 120 mg) is the separate biosimilar for Xgeva, used for cancer-related bone conditions at a higher dose. If you are being treated for osteoporosis, you should receive Jubbonti — not Wyost. Confirm the product and dose with your clinician if you receive any communication about the biosimilar transition.
- 3
Verify your Part B medical-benefit cost-share and Medigap coverage
For UHC Medicare members, Jubbonti/Prolia is a Part B drug billed in the clinic under HCPCS J0897 — not a Part D pharmacy drug. Your cost is the plan's Part B drug copay or 20% coinsurance after the Part B deductible on Original Medicare. The $2,100 Part D cap does not apply. If you have a Medigap supplement, it typically covers the 20%. Call UHC member services at the number on your ID card for an estimate specific to your plan design.
Options if UnitedHealthcare won't cover Prolia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Jubbonti (denosumab-bddz, 60 mg)
The interchangeable biosimilar that now replaces branded Prolia on all UHC Medicare Advantage and most employer-group MA plans as of September 1, 2025. Same denosumab molecule, same 60 mg subcutaneous dose, same q6-month administration schedule. Existing Prolia authorizations transitioned automatically. The treatment itself does not change — only the product label on the vial.
Fosamax (alendronate) — generic bisphosphonate
Oral generic bisphosphonate, Tier 1 on most formularies. Common first-line osteoporosis treatment. Prior bisphosphonate history may be part of the PA documentation review.
Reclast (zoledronic acid)
Annual IV bisphosphonate infusion administered in a clinic and billed under the medical benefit. Typically covered at lower cost-share than Prolia/Jubbonti. An option for patients unable to tolerate oral bisphosphonates.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes, for Medicare Advantage and most employer-group Medicare Advantage members. Per UHCprovider.com, effective September 1, 2025, Jubbonti (denosumab-bddz) replaced branded Prolia as the covered denosumab product. The treatment does not change — same molecule, same 60 mg dose, same in-office injection every 6 months. Existing Prolia authorizations transitioned to Jubbonti automatically. If you are on a non-Medicare commercial plan, verify your current plan's formulary.
Jubbonti (denosumab-bddz, 60 mg) is the interchangeable biosimilar for Prolia, indicated for postmenopausal osteoporosis and related bone-loss conditions. Wyost (denosumab-bddz, 120 mg) is the interchangeable biosimilar for Xgeva, used for cancer-related bone conditions at a higher dose. If you are being treated for osteoporosis, your product should be Jubbonti. Wyost is for oncology bone indications. Both replaced their reference products on UHC Medicare plans effective September 1, 2025.
No. Jubbonti and Prolia are Part B medical-benefit drugs billed in the clinic under HCPCS J0897 for most UHC Medicare members — not Part D pharmacy drugs. The $2,100 Part D out-of-pocket cap (2026) applies to Part D drugs only. Part B cost-sharing on UHC is the plan's Part B drug copay or 20% coinsurance. A Medigap supplement typically covers the 20%. Verify your specific UHC MA plan's cost-share at myuhc.com.
Yes, for most UHC Medicare Advantage and employer-group MA plan members. Per UHC's announcement, existing Prolia authorizations transitioned to Jubbonti automatically as of September 1, 2025. You should not need to obtain a new PA solely because of the biosimilar switch. Confirm the transition was applied to your specific authorization by checking with your prescribing clinician or calling UHC member services.
On a UHC Medicare Advantage plan, observed copays for denosumab clinic injections range $0–$500 per injection depending on plan design — verify on your plan documents at myuhc.com. On Original Medicare, the cost is 20% of the Part B-approved amount after the Part B deductible; a Medigap supplement typically covers this 20%. Cash without coverage is estimated at $1,786–$2,507 per 60 mg dose. All figures are estimates; verify with UHC member services.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with UnitedHealthcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.